Osman Acar

Osman Acar

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
AOAYSEL OZPINAR
AYSEL OZPINAR
CSCeyda Sönmez
Ceyda Sönmez
ABAleyna Baltacioglu
Aleyna Baltacioglu
OAOsman Acar
Osman Acar
MKMeltem Kilercik
Meltem Kilercik
FSFlorian J. Schweigert
Florian J. Schweigert
Oxidative stress and inflammation play central roles in the immunopathogenesis of COVID‐19. In this study, we investigated whether circulating carotenoids, retinol, and vitamin E metabolites can distinguish COVID‐19 patients from healthy controls and discriminate disease severity. We analyzed 44 hospitalized COVID‐19 patients (23 with moderate disease and 21 with severe disease) and 39 healthy controls recruited from the same hospitals. Plasma concentrations of individual carotenoids, retinol, total vitamin A, vitamin E (γ‐tocopherol, α‐tocopherol), retinol‐binding protein 4 (RBP4), transthyretin (TTR), complete blood count parameters, and clinical chemistry and inflammatory markers were determined and statistically analyzed. Compared with healthy controls, COVID‐19 patients had significantly lower concentrations of vitamin E, retinol, total vitamin A, lutein, total carotenoids, and TTR and higher levels of inflammatory markers. In multivariate logistic regression, the RBP4/total vitamin A ratio, γ‐tocopherol, and ferritin emerged as independent factors differentiating COVID‐19 patients from healthy controls. Within the patient group, antioxidant micronutrient levels did not differ significantly between moderate and severe COVID‐19, whereas inflammatory markers, such as C‐reactive protein, ferritin, and the neutrophil‐to‐lymphocyte ratio, increased with severity. These data indicate that although carotenoids, vitamin A, and vitamin E are markedly depleted during COVID‐19, they do not stratify disease severity, whereas the RBP4/total vitamin A ratio, γ‐tocopherol, and ferritin may serve as useful biomarkers for distinguishing COVID‐19 from health.

Verified
Journal Article
Open access
PDF file
ABAleyna Baltacioglu
Aleyna Baltacioglu
OAOsman Acar
Osman Acar
CSCeyda Sönmez
Ceyda Sönmez
YSYeşim Sağlıcan
Yeşim Sağlıcan
ÖAÖmer Burak Argun
Ömer Burak Argun
AOAYSEL OZPINAR
AYSEL OZPINAR
Non-muscle-invasive bladder cancer (NMIBC) is characterized by high recurrence rates and necessitates lifelong cystoscopic surveillance, underscoring the need for minimally invasive biomarkers to improve early detection and risk stratification. Therefore, this study aimed to investigate the role of trimethylamine-N-oxide (TMAO) and its precursors as diagnostic biomarkers for NMIBC. A total of 50 male patients with NMIBC (25 pTa and 25 pT1) were included in this study. Additionally, 52 age-matched healthy individuals were included as controls. Serum TMAO and its dietary precursors were quantified using liquid chromatography–tandem mass spectrometry. Group differences were analyzed using nonparametric tests, associations were assessed using Spearman’s correlation, and diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Multivariate logistic regression was performed to identify independent predictors, and a composite risk score was generated. Serum TMAO, carnitine, and choline levels were significantly higher in patients with NMIBC than in controls (p ≤ 0.0001), whereas betaine showed a nonsignificant trend toward higher levels (p ≥ 0.05). The pathological stage (pTa vs. pT1) showed the strongest correlation with TMAO levels. The ROC analysis revealed that TMAO had the highest individual diagnostic accuracy (area under the curve [AUC] = 0.875, 95% confidence interval [CI] 0.812–0.939), whereas carnitine and choline provided complementary diagnostic performance. In multivariate models, TMAO, carnitine, and choline remained independent predictors of NMIBC (p ≤ 0.0001). A composite risk score integrating all four metabolites demonstrated excellent discriminatory capacity (AUC = 0.958, 95% CI 0.926–0.991). The TMAO metabolic axis can be used as a minimally invasive biomarker panel for NMIBC. Further large, prospective, multicenter studies integrating metabolomic and microbiome profiling are needed to validate the findings.

18 March 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HBHavva Beyter
Havva Beyter
OAOsman Acar
Osman Acar
OPOytun Portakal
Oytun Portakal
ÖGÖzlem Gülbahar
Özlem Gülbahar
GTGulsum Feyza Turkes
Gulsum Feyza Turkes
AOAYSEL OZPINAR
AYSEL OZPINAR
Objectives: This study aimed to determine reference intervals (RI) for thyroid hormones based on thyroid antibody levels using different autoanalyzer kits. Methods: RI for Thyroid-stimulating hormone (TSH), free thyroxine (fT 4 ) and free triiodothyronine (fT 3 ) were determined according to thyroid antibody levels and independently of thyroid antibody levels using the R statistical program and RefineR algorithm. Results: Significant differences in RIs were found between antibody-positive (Ab(+)) and antibody-negative (Ab(–)) individuals. TSH RI varied most notably in Abbott and Siemens analyzers. In females, Abbott showed higher TSH RIs in the Ab(+) group (0.41–7.44 mU/L) than in Ab(–) (0.24–3.50 mU/L). In males, Roche and Beckman exhibited the greatest differences (Roche Ab(+): 0.19–5.77; Ab(–): 0.44–3.63; Beckman Ab(+): 0.12–5.23; Ab(–): 0.39–3.96 mU/L). For fT4, Roche showed increased RIs in females with Ab(+) status (11.42–20.42 vs. 10.34–19.35 pmol/L). In males, Beckman and Siemens autoanalyzers also indicated notable differences. Conclusion: Antibody status significantly affects thyroid hormone RI, particularly for TSH. These findings highlight the need for antibody-specific RI and further standardization in establishing reference intervals.